Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for cognitive impairment in type 2 diabetes mellitus
ChiCTR2200067020Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Anhui Medical University
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of dapagliflozin in type 2 diabetes mellitus (T2DM) and Mild Cognitive Impairment (MCI) (2 arms), sponsored by The Second Affiliated Hospital of Anhui Medical University. Primary endpoints: Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA) and 1 more. Started Jun 2022; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on ChiCTR2200067020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200067020.